{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:29:04Z","timestamp":1778614144608,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijcard.2021.02.022","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T02:57:59Z","timestamp":1613357879000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Effectiveness and safety of infliximab in cardiac Sarcoidosis"],"prefix":"10.1016","volume":"330","author":[{"given":"A.L.M.","family":"Bakker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Azzahhafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Swaans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.G.M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Akdim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2021.02.022_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0010","article-title":"Outcome of implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and meta-analysis","author":"Halawa","year":"2020","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1378\/chest.11-0263","article-title":"Management of Cardiac Sarcoidosis in the United States","volume":"141","author":"Hamzeh","year":"2012","journal-title":"Chest."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac Sarcoidosis","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2021.02.022_bb0025","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCP.0000000000000410","article-title":"Cardiac sarcoidosis: challenges in clinical practice","volume":"23","author":"Bakker","year":"2017","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MCP.0000000000000611","article-title":"Treatment of cardiac sarcoidosis","volume":"25","author":"Kouranos","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac Sarcoidosis","volume":"68","author":"Birnie","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0045","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH)","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0055","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0060","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac Sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0065","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"Muser","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ijcard.2021.02.022_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12350-016-0682-1","article-title":"The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis","volume":"24","author":"Lee","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0075","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0080","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0085","first-page":"1","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis","volume":"3","author":"Baker","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/ehjci\/jex146","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American","volume":"18","author":"Slart","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2021.02.022_bb0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"Osborne","year":"2014","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac Sarcoidosis","volume":"25","author":"Ning","year":"2019","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0105","article-title":"The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis","author":"Flores","year":"2018","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac Sarcoidosis","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2021.02.022_bb0115","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007030","article-title":"Complementary value of cardiac magnetic resonance imaging and positron emission tomography\/computed tomography in the assessment of cardiac Sarcoidosis","volume":"11","author":"Vita","year":"2018","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2021.02.022_bb0125","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321002758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321002758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:52:30Z","timestamp":1759092750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"alternative-id":["S0167527321002758"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.022","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of infliximab in cardiac Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}